Answers are grounded in this paper and cite their sources.
The maintenance of bone health has been a clinical challenge in breast cancer patients receiving adjuvant endocrine treatment. Especially in the setting of hormone receptor-positive breast cancer, treatment with aromatase inhibitors, although highly effective as anti-cancer agents, causes rapid and substantial bone loss. 1 In the bone environment, receptor activator of nuclear factor- κ B ligand (RANKL) is an essential determinant of osteoclast differentiation and activity. Denosumab is a monoclonal antibody directed against RANKL that has been approved for the treatment of both osteoporosis and bone metastases. 1 Although an earlier study had shown a significant increase of 5.5% in bone mineral density (BMD) at the lumbar spine with denosumab in 252 women with non-metastatic breast cancer receiving aromatase inhibitors, 2 this trial was not designed to assess fracture risk.
No takes yet. Share an insight, caveat, or question.
Rachner et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: